Anti-tumour activity of a first-in-class agent NUC-1031 in patients with advanced cancer: results of a phase I study
Sarah P. Blagden(Churchill Hospital), Essam Ghazaly(Queen Mary University of London), Andrea Rockall, Hani Gabra(Royal Children's Hospital), Markand Patel(Hammersmith Hospital), Nagy Habib(Hammersmith Hospital), Laura Spiers(Churchill Hospital), Puvan Suppiah(Hammersmith Hospital), Harpreet Wasan(Peter MacCallum Cancer Centre), Mona El‐Bahrawy(Al-Azhar University), Nishat Bharwani(Imperial College Healthcare NHS Trust), Daniel O’Shea(Wellcome Trust), Ivana Rizzuto(Imperial College Healthcare NHS Trust), Robert Leonard(National Cancer Centre Japan), Ajithkumar Sukumaran(Imperial College London)
Cited by 43
Related Papers
Rethinking ovarian cancer: recommendations for improving outcomes
|Nature reviews. Cancer|2011|1.5k
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
|New England Journal of Medicine|2019|1.5k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k